When evaluated with more sensitive and reliable 24-h continuous monitoring and in thorough QT studies, two of the long-acting GLP-1 RAs, liraglutide and albiglutide, were shown to cause a pronounced increase in the 24-h time-averaged mean HR from baseline of up to 610 bpm, while for dulaglutide and exenatide LAR, the increase in 24-h mean HR was 34 bpm [23, 24, 27,28,29,30]
This causes an increase in glucose-dependent insulin secretion which results in a decrease in glucagon secretion (by stimulating the release of insulin and suppressing the release of glucagon, the body thinks it has enough insulin and the body will in return slow down glucagon production/release)
So its a case of leapfrogging and iterative improvement
Treatment Options for Kidney Infections in Semaglutide Users Kidney infections can be serious, especially for people taking semaglutide
The Phase 3 TRIUMPH-4 data pushed that even higher, to 28.7% at 68 weeks